Patent 12102027

Extensions

Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.

Active provider: Google · gemini-2.5-flash

Extensions

Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.

✓ Generated

To provide a comprehensive analysis of US patent 12102027 from the USPTO database, I will detail any patent term adjustments (PTA), patent term extensions (PTE), continuation applications, divisional applications, related family members, and the projected expiration date.

Patent Term Adjustments (PTA):
Patent Term Adjustment (PTA) is granted to compensate for certain administrative delays by the USPTO during the prosecution of a U.S. utility or plant patent application. This can occur if the USPTO fails to:

  • Issue a first Official Action or notice of allowance within 14 months of filing.
  • Issue an action within four months of an applicant's response to an Official Action.
  • Issue the patent within four months of payment of the issue fee.
  • Issue a patent within 36 months from the filing date of an application.

While the provided Google Patents snippet indicates that US12102027B2 was granted on October 1, 2024, from an application filed on June 23, 2015, it does not explicitly state the amount of PTA awarded. To definitively determine any PTA, one would typically need to review the "Issue Notification Letter" or the patent's file history in USPTO Patent Center.

Patent Term Extensions (PTE):
Patent Term Extension (PTE) is available for patents claiming certain human drug products, animal drug products, biological veterinary products, medical device products, and food or color additive products. It aims to restore patent term lost due to premarket regulatory review by agencies like the FDA. The maximum extension permitted is 5 years.

Based on the nature of US12102027B2, "System and method for prescriptive seed treatment," it is unlikely to be eligible for PTE, as it does not appear to cover products subject to premarket government approval by a regulatory agency like the FDA. PTE is primarily for pharmaceutical and medical device patents. The provided information does not indicate any PTE for this patent.

Continuation and Divisional Applications:
The provided information lists US15/739,606 as the application number for US12102027B2. It also lists US20180192577A1 as another version. US20180192577A1 is a patent application publication, suggesting it is an earlier publication of the same application, rather than a continuation or divisional application. Continuation or divisional applications would typically have distinct application numbers but claim priority to an earlier-filed "parent" application. Without further data from the USPTO file wrapper, it cannot be definitively determined if any continuation or divisional applications exist.

Related Family Members:
The Google Patents entry states, "Family has litigation," and refers to a Darts-ip link for "First worldwide family litigation filed." This indicates that there are likely related patent family members in other jurisdictions, or potentially other US patents stemming from the same priority application. However, the provided text does not explicitly list these related family members.

Projected Expiration Date:
The legal status information provided states that US12102027B2 is "Active" and "expires 2035-12-07." This is the projected expiration date. The standard term for utility patents is 20 years from the earliest filing date, with adjustments for USPTO delays (PTA) or regulatory review periods (PTE). Since the application filing date was June 23, 2015, and the patent expires on December 7, 2035, this implies a potential adjustment to the standard 20-year term.

Generated 5/18/2026, 6:48:00 PM